SITC 2025

Nov 5 - 9, 2025 | National Harbor, MD

The agents listed below are currently under investigation. Their safety and efficacy have not been established.

Preclinical Antitumor Activity of Potent and Orally Bioavailable PROTAC HPK1 Degraders as Monotherapy or Combined With an Anti-PD-1 Antibody

W Corwin et al.